Response evaluation of locoregional therapies in combined hepatocellular–cholangiocarcinoma and intrahepatic cholangiocarcinoma versus hepatocellular carcinoma: a propensity score matched study

To evaluate the response of locoregional therapy (LRT) on combined hepatocellular–cholangiocarcinoma (cHCC-CC) and intrahepatic cholangiocarcinoma (IHC) and compare their outcomes with propensity matched hepatocellular carcinoma (HCC) patients. From January 2011 to July 2020, 13 patients with cHCC-C...

Full description

Saved in:
Bibliographic Details
Published in:Clinical radiology 2022-02, Vol.77 (2), p.121-129
Main Authors: Mukund, A., V. Srinivasan, S., Rana, S., Vijayaraghavan, R., Patidar, Y., Arora, V., Jindal, A., Choudhury, A., Shasthry, S.M., Sarin, S.K.
Format: Article
Language:English
Subjects:
Ablation Techniques - methods
Aged
Bile Duct Neoplasms - complications
Bile Duct Neoplasms - surgery
Bile Duct Neoplasms - therapy
Bile Ducts, Intrahepatic - surgery
Carcinoma, Hepatocellular - complications
Carcinoma, Hepatocellular - surgery
Carcinoma, Hepatocellular - therapy
Chemoembolization, Therapeutic - methods
Cholangiocarcinoma - complications
Cholangiocarcinoma - surgery
Cholangiocarcinoma - therapy
Female
Humans
Liver Neoplasms - complications
Liver Neoplasms - surgery
Liver Neoplasms - therapy
Male
Middle Aged
Propensity Score
Radiofrequency Ablation
Retrospective Studies
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the response of locoregional therapy (LRT) on combined hepatocellular–cholangiocarcinoma (cHCC-CC) and intrahepatic cholangiocarcinoma (IHC) and compare their outcomes with propensity matched hepatocellular carcinoma (HCC) patients. From January 2011 to July 2020, 13 patients with cHCC-CC (11 men, two women, median age 56 years) and 15 IHC patients (10 men, five women, median age 60 years) were compared with 101 HCC patients (79 men, 22 women, median age 60 years) after LRT. All tumours were proven histologically. Among the 13 cHCC-CC patients, 11 received transarterial chemoembolisation (TACE), one received microwave ablation (MWA) and one received TACE with radiofrequency ablation (RFA). Of 15 IHC patients, eight received TACE, five received RFA, and one received MWA, and one received TACE with RFA. Propensity score matching (PSM) was done with conditional logistic regression adjusted for age, type of LRT, tumour specific features and Child–Pugh score. After LRT, on univariate analysis an objective response was seen in 30% of cHCC-CC and 53% of IHC patients. PSM analysis demonstrated shorter progression-free survival (PFS; cHCC-CC versus HCC: 1.5 versus 7.5 months; IHC versus HCC: 6 versus 14 months, p
ISSN:0009-9260
1365-229X
DOI:10.1016/j.crad.2021.10.013